Dem IPB wird erneut ein beispielhaftes Handeln im Sinne einer chancengleichheitsorientierten Personal- und Organisationspolitik bescheinigt. Das Institut erhält zum 6. Mal in Folge das TOTAL E-QUALITY…
Die Plant Science Student Conference (PSSC) wird seit 20 Jahren im jährlichen Wechsel von Studierenden der beiden Leibniz-Institute IPK und IPB organisiert. Im Interview erläutern Christina Wäsch…
Schneider, A.; Wessjohann, L. A.;Comparison of impurity profiles of Orlistat pharmaceutical products using HPLC tandem mass spectrometryJ. Pharm. Biomed. Anal.53767-772(2010)DOI: 10.1016/j.jpba.2010.05.010
HPLC-UV and MS/MS studies of impurity profiles of original (Xenical®, F. Hoffmann-La Roche Ltd., Switzerland) and generic (Cobese™, Ranbaxy Laboratories Limited, India, and Orsoten, KRKA, Russia) products were carried out. The drug and related impurities were extracted by dissolving commercial samples in ethanol. The generic formulations contained higher levels of impurities than the original product. Impurity profiles (HPLC-MS/MS) of the generic samples are similar among themselves, whilst different in comparison to the impurity profile of the original product. The number of detected impurities for generics (14 impurities in Cobese™ and 13 impurities in Orsoten) is higher than for the original product (3 impurities in Xenical®). Based on these analyses the overall analytical quality follows the order Xenical® (best) > Orsoten > Cobese™.